Transforming a human enzyme to break down toxic chemicals
Converting human butyrylcholinesterase into a metalloenzyme for catalytic hydrolysis of organophosphates
This study is looking at ways to make a special enzyme better at breaking down harmful chemicals found in pesticides and nerve agents, so it can help people who have been exposed to these toxins feel safer and healthier.
Quick facts
| Grant type | R21 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of California Los Angeles NIH-funded |
| Lab location | 1 site (Los Angeles, United States) |
| Project ID | NIH-10928701 on NIH RePORTER |
What this research studies
This research focuses on modifying the human enzyme butyrylcholinesterase (BChE) to enhance its ability to break down toxic organophosphate compounds, which are harmful chemicals found in pesticides and nerve agents. By introducing specific mutations and using oxime compounds, the goal is to create a more effective therapeutic enzyme that can degrade these toxins in the bloodstream. This approach aims to improve the enzyme's effectiveness while minimizing potential side effects, making it a safer option for patients exposed to these harmful substances.
Who could benefit from this research
Good fit: Ideal candidates for this research include military personnel and civilians who may be at risk of exposure to organophosphate toxins.
Not a fit: Patients who have not been exposed to organophosphate compounds or those with unrelated health conditions may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could provide a new treatment option for individuals exposed to toxic organophosphate compounds, potentially saving lives and reducing long-term health effects.
How similar studies have performed: Previous research has shown promise in modifying enzymes for enhanced catalytic activity, indicating that this approach may lead to successful outcomes.
Where this research is happening
Los Angeles, United States
- University of California Los Angeles — Los Angeles, United States (Active)
Researchers
- Principal investigator: Shafaat, Hannah S — University of California Los Angeles
- Study coordinator: Shafaat, Hannah S
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.